Fibrinogen (human) LANCE Ultra TR-FRET Detection Kit, 500 Assay Points

The LANCE® Ultra Human Fibrinogen Detection Kit is designed for detection and quantitation of human fibrinogen in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

• No-wash steps, no separation steps
• TR-FRET technology
• Sensitive detection
• High reproducibility
• Faster time-to-results
• Easy automation
• 96-well, 384-well, and 1536-well formats

LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

Plasma fibrinogen is a large hexamer glycoprotein (Mr=340,000), containing two sets of three different chains (α, β, and γ). Synthesized in the liver and circulating at a concentration of around 2-4 mg/ml, it plays a role in blood clotting and inflammation. During normal blood coagulation, a cascade activates the prothrombin to convert soluble fibrinogen into insoluble fibrin strands. These strands are then cross-linked by factor XIII to form a blood clot. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, displaying vasoconstrictor and chemotactic activities. Many studies have shown that elevated fibrinogen is a major risk factor for atherosclerosis and associated with an increased risk of ischemic heart disease (IHD), stroke and other thromboembolism. Low plasma fibrinogen concentrations are associated with an increased risk of bleeding due to impaired primary and secondary hemostasis.